Monoclonal pathogenic antibodies to the thyroid-stimulating hormone receptor in Graves' disease with potent thyroid-stimulating activity but differential blocking activity activate multiple signaling pathways.
The thyroid target Ag for disease-inducing autoantibodies in Graves' disease is the receptor for thyroid-stimulating hormone (TSH), but little is known about the molecular basis of this pathogenic Ab response. We describe the characteristics of two high- affinity mAbs developed from an experimental murine model of hyperthyroid Graves' disease that exhibit potent thyroid-stimulating activity. Nanogram concentrations of the IgG mAbs KSAb1 and KSAb2 and their Fab induce full stimulation of the TSH receptor that is matched by the ligand TSH and, thus, act as full agonists for the receptor. However, KSAb1 and KSAb2 display differential activities in their ability to block TSH-mediated stimulation of the receptor, indicating subtle differences in their biological properties. In displacement studies, IgG and Fabs of KSAb1 and KSAb2 compete with Graves' disease autoantibodies as well as thyroid-blocking Abs present in some hypothyroid patients, indicating a close relationship between these autoimmune determinants on the receptor. In passive transfer studies, single injections of microgram quantities of KSAb1 or KSAb2 IgG led to rapid elevation of serum thyroxine and a hyperthyroid state that was maintained for a number of days. The thyroid glands showed evidence of cell necrosis, but there was no accompanying mononuclear cell infiltrate. In studying their receptor activation pathways, both KSAb1 and KSAb2 provoked phosphorylation of the intracellular ERK1/2 pathway in primary thyrocytes, indicating that multiple signaling pathways may participate in the pathogenesis of Graves' disease. In summary, our findings emphasize the similarities of the experimental mouse model in reproducing the human disorder and provide improved means for characterizing the molecular basis of this pathogenic response.
Gilbert
Jacqueline A
JA
King's College London, Division of Gene and Cell Based Therapy, King's College School of Medicine, London, United Kingdom.
Gianoukakis
Andrew G
AG
Salehi
Siamak
S
Moorhead
Jane
J
Rao
Prakash V
PV
Khan
M Zareen
MZ
McGregor
Alan M
AM
Smith
Terry J
TJ
Banga
J Paul
JP
D000818:Animals; D000911:Antibodies, Monoclonal / Q000097:blood*; D000915:Antibody Affinity; D001323:Autoantibodies / Q000097:blood*; D001667:Binding, Competitive; D004195:Disease Models, Animal; D005260:Female; D006111:Graves Disease / Q000276:immunology* / Q000473:pathology; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D007116:Immunization, Passive; D018828:Immunoglobulins, Thyroid-Stimulating; D020935:MAP Kinase Signaling System; D051379:Mice; D008807:Mice, Inbred BALB C; D011989:Receptors, Thyrotropin / Q000097:blood / Q000276:immunology*; D015398:Signal Transduction; D013961:Thyroid Gland / Q000276:immunology / Q000473:pathology
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D018828:Immunoglobulins, Thyroid-Stimulating; D011989:Receptors, Thyrotropin; C094372:thyrotropin-binding inhibitory immunoglobulin